Effects of aspirin on cancer initiation and progression

Expert Review of Anticancer Therapy

Volumn 13, Issue 2, 2013, Pages 115-117

  Choe, Kevin S ^a   Liauw, Stanley L ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

anticoagulant; antiplatelet; aspirin; cancer; chemoprevention; coagulation; COX2; radiation

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2; PLACEBO;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER GROWTH; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER SURVIVAL; COLORECTAL ADENOMA; COLORECTAL CANCER; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; LONG TERM CARE; LOW DRUG DOSE; METASTASIS; NONHUMAN; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT CANCER; REVIEW; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS; ASPIRIN; CYCLOOXYGENASE 2 INHIBITORS; DISEASE PROGRESSION; HUMANS; MALE; NEOPLASMS; PLATELET AGGREGATION INHIBITORS; PROSTATIC NEOPLASMS;

EID: 84873930044     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.12.166     Document Type: Review

References (24)

1. Tagalakis V, Blostein M, Robinson-Cohen C, Kahn SR. The effect of anticoagulants on cancer risk and survival: systematic review. Cancer Treat. Rev. 33(4), 358-368 (2007).
2. Kuderer NM, Ortel TL, Francis CW. Impact of venous thromboembolism and anticoagulation on cancer and cancer survival. J. Clin. Oncol. 27(29), 4902-4911 (2009).
3. Thun MJ, Namboodiri MM, Heath CW Jr. Aspirin use and reduced risk of fatal colon cancer. N. Engl. J. Med. 325(23), 1593-1596 (1991).
4. Jacobs EJ, Thun MJ, Bain EB, Rodriguez C, Henley SJ, Calle EE. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J. Natl Cancer Inst. 99(8), 608-615 (2007).
5. Sandler RS, Halabi S, Baron JA et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N. Engl. J. Med. 348(10), 883-890 (2003).
6. Rothwell PM, Price J F, Fowkes FG et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefts in 51 randomised controlled trials. Lancet 379(9826), 1602-1612 (2012).
7. Rothwell PM, Fowkes FG, Belch J F, Ogawa H, Warlow C P, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 377(9759), 31-41 (2011).
8. Rothwell PM, Wilson M, Price J F, Belch J F, Meade T W, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 379(9826), 1591-1601 (2012).
9. Choe KS, Cowan JE, Chan JM, Carroll PR, D'Amico AV, Liauw SL. Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy. J. Clin. Oncol. 30(28), 3540-3544 (2012).
10. Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D, Hankinson SE. Aspirin intake and survival after breast cancer. J. Clin. Oncol. 28(9), 1467-1472 (2010).
11. Thun MJ, Jacobs EJ, Patrono C. The role of aspirin in cancer prevention. Nat. Rev. Clin. Oncol. 9(5), 259-267 (2012).
12. + uptake: inhibition by salicylate. J. Physiol. (Lond.) 571(Pt 1), 57-73 (2006).
13. Mahdi JG, Alkarrawi MA, Mahdi AJ, Bowen ID, Humam D. Calcium salicylate-mediated apoptosis in human HT-1080 fbrosarcoma cells. Cell Prolif. 39(4), 249-260 (2006).
14. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-infammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J. Natl Cancer Inst. 94(4), 252-266 (2002).
15. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N. Engl. J. Med. 356(21), 2131-2142 (2007).
16. Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 20(5), 576-590 (2011).
17. Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat. Rev. Cancer 11(2), 123-134 (2011).
18. Dixon DA, Tolley ND, Bemis-Standoli K et al. Expression of COX-2 in platelet-monocyte interactions occurs via combinatorial regulation involving adhesion and cytokine signaling. J. Clin. Invest. 116(10), 2727-2738 (2006).
19. Stone RL, Nick AM, McNeish IA et al. Paraneoplastic thrombocytosis in ovarian cancer. N. Engl. J. Med. 366(7), 610-618 (2012).
20. Borsig L. The role of platelet activation in tumor metastasis. Expert Rev. Anticancer Ther. 8(8), 1247-1255 (2008).
21. Gasic GJ, Gasic TB, Stewart CC. Antimetastatic effects associated with platelet reduction. Proc. Natl Acad. Sci. USA 61(1), 46-52 (1968).
22. Cook NR, Lee IM, Gaziano JM et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 294(1), 47-55 (2005).
23. Sanmuganathan PS, Ghahramani P, Jackson PR, Wallis EJ, Ramsay LE. Aspirin for primary prevention of coronary heart disease: safety and absolute beneft related to coronary risk derived from meta-analysis of randomised trials. Heart 85(3), 265-271 (2001).
24. McQuaid KR, Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am. J. Med. 119(8), 624-638 (2006).